Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Joshua Higa - Vice President, Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Dae Gon Ha - Stifel Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Joon Lee - Truist Maury Raycroft - Jefferies Will Soghikian - Leerink Partners Yaron Werber - TD Cowen Michael Riad - Morgan Stanley Jack Allen - Baird Lisa Walter - RBC Operator Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.25 per share a year ago.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ultragenyx (RARE) Posts New Data From Bone Disease Study
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Ultragenyx Pharmaceutical Inc. revenues from regulatory approved drugs in Q1 of 2024 were $109 million, representing sales growth of 8% compared to the same time period in 2023. Setrusumab is an anti-sclerostin monoclonal antibody being developed for the treatment of patients with osteogenesis imperfecta. DTX-401 is another promising program in the pipeline being developed for the treatment of patients with glycogen storage disease type Ia.
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
